June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Incidence of Retinal Detachment in Type 1 and Type 2 Stickler Syndrome
Author Affiliations & Notes
  • Jessica Kraker
    Ophthalmology, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Mona Amer
    University of Louisville School of Medicine, Louisville, Kentucky, United States
  • Lisa Schimmenti
    Clinical Genomics, Mayo Clinic Minnesota, Rochester, Minnesota, United States
    Biochemistry and Molecular Biology, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Mary Elizabeth Hartnett
    Ophthalmology and Visual Sciences, University of Utah Health, Salt Lake City, Utah, United States
  • Eileen Hwang
    Ophthalmology and Visual Sciences, University of Utah Health, Salt Lake City, Utah, United States
  • Footnotes
    Commercial Relationships   Jessica Kraker None; Mona Amer None; Lisa Schimmenti None; Mary Elizabeth Hartnett None; Eileen Hwang None
  • Footnotes
    Support  RO1EY015130, R01EY0117011, National Institutes of Health Core Grant EY014800, and an Unrestricted Grant from Research to Prevent Blindness,
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 146 – A0326. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jessica Kraker, Mona Amer, Lisa Schimmenti, Mary Elizabeth Hartnett, Eileen Hwang; Incidence of Retinal Detachment in Type 1 and Type 2 Stickler Syndrome. Invest. Ophthalmol. Vis. Sci. 2022;63(7):146 – A0326.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Patients with Stickler syndrome are at increased risk of retinal detachment (RD). The vast majority of Stickler syndrome is due to mutations in COL2A1 and COL11A1, which are responsible for type 1 and type 2 Stickler syndrome, respectively. Few studies have examined patients that had RD prior to presentation, or incident RD, in COL11A1 patients.

Methods : Descriptive retrospective case series of patients with mutations in COL2A1 and COL11A1 presenting to the University of Utah without an incident RD from 2010 to 2020.

Results : 3 of 10 COL2A1 patients who received bilateral prophylactic laser or cryotherapy developed RD. Of these 3 COL2A1 patients with post-prophylaxis RD, all 3 received 360 cryotherapy and developed RD 2 weeks, 3 months, and 2 years after prophylaxis. 2 of 8 COL2A1 patients who did not initially receive prophylaxis developed RD. 0 of 6 COL11A1 subjects who received prophylaxis developed RD and 0 of 5 COL11A1 subjects who did not initially receive prophylaxis developed RD. The average length of follow-up was 5.7 +/- 5.3 years for COL2A1 patients and 7.1 +/- 4.1 years for COL11A1 patients.

Conclusions : In our sample, despite prophylactic treatment, incidence of RD in patients with COL2A1 mutations was higher compared to patients with COL11A1 mutations. We also noted a high rate of RD occurring soon after 360 cryotherapy prophylaxis.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×